AN9025 Key Features - AN9025 is a novel pan-RAS(ON) inhibitor developed by Adlai Nortye with improved potency and a favorable PK/PD profile[8, 16] - AN9025 strongly binds to cyclophilin A (CypA) with a dissociation constant (KD1) of 3.2 nM, exhibiting a 4-fold stronger binding affinity compared to RMC-6236[3, 4, 8] - AN9025 exhibits a 3- to 8-fold higher binding affinity for tri-complex formation compared to RMC-6236[5] - AN9025 demonstrates approximately 100-fold greater potency in inhibiting cell viability across RAS-mutant cell lines compared to RMC-6236[8] - AN9025 shows potent anti-proliferative activity in RAS-addicted cancer cell lines with picomolar IC50 values[7, 8] In Vivo Efficacy and PK/PD - In vivo studies show that AN9025 induces deep tumor regression, with efficacy comparable to or exceeding RMC-6236 in mouse CDX models[8, 9] - AN9025 demonstrates a favorable pharmacokinetic (PK) and pharmacodynamic (PD) profile in vivo[8] - AN9025 exhibits more sustained DUSP6 inhibition compared to RMC-6236 across all tested doses[8] Clinical Development - The prolonged tumor DUSP6 suppression following AN9025 administration suggests the potential for an intermittent dosing regimen to optimize tolerability and efficacy[8] - AN9025 is advancing through the IND-enabling stage[8] - Adlai Nortye is actively seeking strategic partnerships to advance the development of AN9025[18]

Company Overview - Air Lease Corporation (ALC) operates as an aircraft leasing platform with approximately $55 billion in assets [9, 11, 133] - The company's aircraft utilization rate was 99.7% in Q4 2022 [10, 14] - ALC maintains investment-grade credit ratings from S&P (BBB), Fitch (BBB), and Kroll (A-) [10, 133] - The company has $6.9 billion in total available liquidity [10, 14, 108] - ALC has a diversified customer base, serving 117 airlines in 62 countries [14, 61, 133] Financial Performance - ALC's adjusted pre-tax return on common equity was 11.0% [10, 137] - The company's total assets amounted to $28.4 billion [10, 77, 133] - ALC's unsecured debt represents 99% of its debt portfolio [10, 96, 105] - The company's fixed-rate debt accounts for 91% of its total debt [10, 98, 105] - Adjusted net income before income taxes was $659.9 million in 2022 [135, 137] Portfolio and Order Book - ALC has commitments to purchase 398 aircraft from Boeing and Airbus for delivery through 2029, with an estimated aggregate commitment of $25.5 billion [10, 11] - The company has $31.4 billion in committed minimum future rentals [10, 61] - 90% of ALC's order book through 2024 is placed on long-term leases [10, 14, 70, 71]

Company Overview - Air Lease Corporation (ALC) is a significant aircraft leasing platform with over $55 billion in assets and commitments [10] - The company has a strong order book of 430 aircraft [11, 12] with an estimated aggregate commitment of $276 billion [12] - ALC boasts $76 billion in liquidity, comprising $1 billion in unrestricted cash and $66 billion in available borrowing capacity [11, 12] - Approximately 72% of ALC's fleet NBV is with flag carriers or airlines with government ownership [11] Financial Performance and Market Position - ALC's revenue increased from $2 billion in 2020 to $23 billion in the trailing twelve months (TTM) ending June 30, 2022 [14] - The company's orderbook placement rate rose from 47% in 2020 to 58% in Q2 2022 (TTM) [14] - Operating cash flow increased from $11 billion in 2020 to $15 billion in Q2 2022 (TTM) [14] - Adjusted Pre-tax Return on Common Equity is 122% [11, 42] Industry Trends and Outlook - International passenger volumes are recovering, reaching -29% of 2019 levels [14, 23] - The industry experienced a 658% decline in passenger traffic during the COVID-19 pandemic [27] - ALC has $10 billion in orderbook placements since June 2021 [38]

Company Overview - Air Lease Corporation (ALC) has $185 billion in total assets[12] - ALC has $257 billion in committed minimum future fleet rentals[12] - ALC's order book is 91% placed through 2020[12] - ALC has $43 billion in available liquidity[12] Financial Performance - ALC's adjusted pre-tax ROE is 155%[12] - The adjusted net income before income taxes was $690322 million in 2018[76] - The adjusted diluted EPS before income taxes was $620 in 2018[76] Fleet and Portfolio - ALC owns 275 aircraft with a weighted average age of 38 years[12,57] - ALC manages 61 aircraft[12,57] - The weighted average lease term remaining is 68 years[12,57] Capital Structure - ALC's debt to equity ratio is 240x[12,62] - Unsecured debt accounts for 69% of the total capitalization[62] - Fixed rate debt accounts for 864% of the total debt[62,71]

Company Overview - Air Lease Corporation (ALC) is a premier aircraft lessor with a globally diversified customer base [10] - ALC has total assets of $156 billion [12] - ALC has $15 billion in total revenues [12] - ALC has $234 billion in committed minimum future fleet rentals [12] Portfolio and Fleet - ALC's owned fleet consists of 244 aircraft with a weighted average age of 38 years and a weighted average remaining lease term of 68 years [12] - ALC manages 50 aircraft [12] - ALC has 368 aircraft on order, with 97% of the order book placed through 2019 [12] - The fleet is geographically diverse, with Europe accounting for 32%, China for 21%, and Asia (excluding China) for 22% [55] Financial Performance - ALC's adjusted pre-tax ROE is 175% [12] - ALC has $32 billion in available liquidity [12] - The company's debt-to-equity ratio is 235x [12] - The adjusted margin before income taxes for fiscal year 2017 was 434% [73]

Financial Data and Key Metrics Changes - For fiscal year 2025, the company reported total revenue of $70.2 million, a slight decline from $72.5 million in fiscal year 2024, primarily due to the exit from the Middle East business [12] - Core adjusted EBITDA reached $7.4 million, an increase of 365% from $1.6 million in the previous year, exceeding guidance of $6 million to $7 million [4][15] - The company ended the year with $2.8 million in cash and $1.1 million in long-term debt, providing flexibility for ongoing initiatives [15] Business Line Data and Key Metrics Changes - North America revenue grew 15% year over year from $57 million to $65.5 million, highlighting strong momentum in core markets [7][12] - The company has shifted focus to private equity-backed companies and exited lower-value, non-core geographies, which has strengthened its business model [5][6] Market Data and Key Metrics Changes - North America now represents over 93.3% of the company's revenue base, indicating a significant concentration in this market [6] - The company is seeing increased adoption of large-scale digital transformation initiatives among clients, reflecting a growing demand for its services [6][17] Company Strategy and Development Direction - The company has made intentional decisions to sharpen its strategy by focusing on core business areas and exiting non-core markets [5] - A new AI-centered global capability center framework has been launched, integrating intelligent automation and data-driven decision systems [10][11] - The company plans to continue hiring key personnel with relationships in the private equity industry to expand its pipeline and network [6][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in fiscal year 2026, projecting revenue between $74 million and $80 million and adjusted EBITDA between $6 million and $8 million [16][17] - The company is experiencing strong traction with clients, with existing clients deepening their partnerships and an expanding private equity network [17][18] Other Important Information - The restructuring process is complete, and stock-based compensation is expected to be significantly lower moving forward [13][15] - Fiscal year 2025 will be the last year to report core adjusted EBITDA as a separate metric, transitioning to adjusted EBITDA and GAAP measures [15] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session.

Financial Data and Key Metrics Changes - For fiscal year 2025, the company reported total revenue of $70.2 million, a decrease from $72.5 million in fiscal year 2024, primarily due to the exit from the Middle East business [11] - Core adjusted EBITDA reached $7.4 million, an increase of 365% from $1.6 million in the previous year, exceeding guidance [14] - The company ended the year with $2.8 million in cash and $1.1 million in long-term debt, providing flexibility for ongoing initiatives [14] Business Line Data and Key Metrics Changes - North America revenue grew 15% year over year from $57 million to $65.5 million, highlighting strong momentum in core markets [11][7] - The company has shifted focus to private equity-backed companies, enhancing its global capability center (GCC) model, which is now a preferred method for scalable capabilities in technology and operations [6][7] Market Data and Key Metrics Changes - North America now represents over 93.3% of the company's revenue base, indicating a significant concentration in this market [6] - The company is experiencing high client retention and increased adoption of large-scale digital transformation initiatives [6] Company Strategy and Development Direction - The company has exited lower-value, non-core geographies, specifically the Middle East consulting market, and has completed associated write-offs [5] - A new AI-centered GCC framework has been launched, integrating intelligent automation and data-driven decision systems to enhance client capabilities [9][10] - The company plans to continue hiring key personnel with relationships in the private equity industry to expand its pipeline and network [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in fiscal year 2026, projecting revenue between $74 million and $80 million and adjusted EBITDA between $6 million and $8 million [15][16] - The company is seeing strong traction with clients, with existing clients deepening partnerships and an expanding private equity network [16] - The cost structure is now lean, and AI-led transformation is gaining pace, indicating a positive outlook for future performance [17] Other Important Information - The restructuring process is complete, and stock-based compensation is expected to be significantly lower moving forward [12] - Fiscal year 2025 will be the last year to report core adjusted EBITDA as a separate metric, transitioning to adjusted EBITDA and GAAP measures [14] Q&A Session Summary - No specific questions or answers were provided in the content, indicating that the call concluded without a Q&A segment [19]

R&D Strategy and Pipeline - BeiGene's R&D strategy focuses on developing a deep and impactful portfolio, executing fast-to-PoC for value maximization, initiating combination therapies early, and advancing only transformative medicines to late-stage development[18] - BeiGene has an extensive investment in innovative platforms, supporting a robust preclinical pipeline of 69 programs, with 51% biologics and 43% small molecules[19, 20] - BeiGene is transforming its pipeline with a focus on heme leadership and solid tumor diversification, expecting POC data readouts for many NMEs in the next 1-2 years[21] Solid Tumor Programs - BGB-43395 (CDK4i) is undergoing dose escalation in monotherapy and in combination with endocrine therapy (ET) in breast cancer patients[34] - Preliminary data from the BGB-43395-101 study shows a manageable safety profile, with diarrhea and nausea being the most commonly reported AEs[28] - BGB-43395 exhibits rapid absorption with a median Tmax of approximately 2 hours, and exposures increased approximately dose proportionately[42] Hematology Programs - Brukinsa (Zanubrutinib) - Brukinsa has demonstrated sustained PFS superiority over Ibrutinib in the ALPINE H2H study with 42.5 months follow-up, with a HR of 0.68 (95% CI: 0.54, 0.84)[74] - In the ALPINE study, Zanubrutinib showed sustained superiority and risk reduction in the TP53/Del17p population, with a HR of 0.51 (95% CI: 0.33, 0.78)[78, 80] - In the SEQUOIA study, Zanubrutinib demonstrated a sustained PFS benefit in treatment-naive unfit CLL/SLL patients, with a 71% reduction in risk of progression or death[88, 96] Hematology Programs - Sonrotoclax - In a Phase 1/1b study, Sonrotoclax combined with Zanubrutinib as frontline treatment for CLL demonstrated high MRD clearance rates, with 90% achieving uMRD by week 48 in the 320mg cohort[68, 122] - The CELESTIAL-TNCLL trial is an ongoing Phase 3 study assessing Sonrotoclax + Zanubrutinib vs Venetoclax + Obinutuzumab for treatment-naive CLL[68, 142] Hematology Programs - BTK CDAC (BGB-16673) - In a Phase 1 study, the BTK degrader BGB-16673 showed an ORR of 77.6% in heavily pre-treated R/R CLL/SLL patients, with an ORR of 93.8% at 200 mg[169, 181] - BGB-16673 demonstrated promising activity in patients with Richter Transformation, with an ORR of 58.3%[175, 180] - BGB-16673 also showed high overall response rates and VGPRs in R/R WM patients, with an ORR of 81.5%[190, 193]

Strategy and Performance - Phillips 66's TSR outperformed its synthetic proxy peer median by 22% (67% vs 45%) since the 2022 CEO transition[18] - The company's integrated model results in a 39% higher return of capital to shareholders compared to its weighted proxy peer average over the last 10 years (646% vs 465%)[20, 21] - Phillips 66's average return on capital employed is 44% higher than its weighted proxy peer average over the last 10 years (107% vs 74%)[22, 23] - The company has a 15% compound annual growth rate (CAGR) in dividends[32, 36] - Phillips 66 has repurchased 35% of its initial shares outstanding since the 2012 spin-off[36] Refining - Phillips 66 aims to reduce refining costs to $550 per barrel by 2027[51] - The company reduced refining costs from $698 per barrel to $590 per barrel[50] - Every $050 per barrel of cost reduction is expected to improve adjusted EBITDA by approximately $315 million[66] Midstream - Phillips 66 projects Midstream adjusted EBITDA growth since 2021[78] - The company is projecting $975 million in Midstream capital spend in 2025[90] Chemicals - CPChem is expected to add approximately 7 million metric tons per annum (MMTA) of capacity through self-funded organic growth from 2017 to 2027[101, 143] - CPChem anticipates a 19% chain margin recovery by 2027[143] Synergies and Capital Allocation - Phillips 66 generates over $500 million in annual operating synergies through integration[106] - The company targets returning over 50% of net operating cash flow to shareholders[53, 114, 119]

AFM24 (EGFR) + atezolizumab in NSCLC - In EGFRwt NSCLC, the Disease Control Rate (DCR) was 76% (25/33 patients), with 48% (16/33) showing tumor shrinkage and an Objective Response Rate (ORR) of 21% (1 CR, 6 PRs)[16] - In EGFRmut NSCLC, the DCR was 71%, with 41% (7/17) showing tumor shrinkage and an ORR of 24% (1 CR, 3 PRs)[16] - Preliminary median Progression-Free Survival (PFS) in EGFRwt NSCLC was 5.6 months, with 36% of patients ongoing[33, 49] - Patients without prior taxane exposure in EGFRwt NSCLC showed a 25% ORR and a preliminary median PFS of 74 months[47, 53] - Post-hoc analysis showed increasing AFM24 exposure resulted in higher ORR, with the highest exposure group (Q4) achieving a 5455% ORR and a 9091% DCR[68] Acimtamig (AFM13) + AlloNK® in r/r HL - In relapsed/refractory Hodgkin Lymphoma (r/r HL), the ORR was 864% (19/22 patients), including a 545% Complete Response (CR) rate[16, 91] - All patients in the LuminICE-203 study were refractory to brentuximab vedotin (BV) and checkpoint inhibitors (CPIs)[80] AFM28 in r/r AML - In the highest dose level (300 mg), a composite complete remission rate (CRcR) of 40% (4/10 patients) was achieved in relapsed/refractory Acute Myeloid Leukemia (r/r AML)[16, 107]